WO2005121350A1 - Preparation of optically active alcohols with whole-cell catalysts - Google Patents

Preparation of optically active alcohols with whole-cell catalysts Download PDF

Info

Publication number
WO2005121350A1
WO2005121350A1 PCT/EP2005/006215 EP2005006215W WO2005121350A1 WO 2005121350 A1 WO2005121350 A1 WO 2005121350A1 EP 2005006215 W EP2005006215 W EP 2005006215W WO 2005121350 A1 WO2005121350 A1 WO 2005121350A1
Authority
WO
WIPO (PCT)
Prior art keywords
whole
process according
cofactor
dehydrogenase
alcohol dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/006215
Other languages
French (fr)
Inventor
Harald GRÖGER
Oliver May
Claudia Rollmann
Francoise Chamouleau
Nicolas Orologas
Karlheinz Drauz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa GmbH filed Critical Degussa GmbH
Priority to AT05757030T priority Critical patent/ATE491036T1/en
Priority to CN200580019379XA priority patent/CN101098967B/en
Priority to DE602005025225T priority patent/DE602005025225D1/en
Priority to JP2007515834A priority patent/JP2008502334A/en
Priority to US11/629,407 priority patent/US20090258405A1/en
Priority to EP05757030A priority patent/EP1774009B1/en
Publication of WO2005121350A1 publication Critical patent/WO2005121350A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/02Preparation of oxygen-containing organic compounds containing a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/02Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/22Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic

Definitions

  • the present invention relates to a process for the preparation of optically active alcohols, starting from ketones, in the presence of a whole-cell catalyst comprising an alcohol dehydrogenase and also an enzyme capable of cofactor regeneration, which process is distinguished in that it is carried out at high substrate concentrations of >500 mM (without the addition of a cofactor) .
  • optically active alcohols are of interest, for example, for the pharmaceuticals industry and the foodstuffs industry.
  • a preferred form of preparation is to obtain the optically active alcohols by reduction of ketones in the presence of alcohol dehydrogenases. This enzymatic reduction of ketones has already been described in detail in the literature. For example, reference may be made here to the overview articles by M.-R. Kula, U. Kragl, Dehydrogenases in the Synthesis of Chiral Compounds in Stereoselective Biocatalysis (ed. : R. N. Patel) , Dekker, 2000, Chapter 28, p. 839-866 and J. D.
  • recombinant expression systems because high rates of expression can be achieved therewith.
  • non-recombinant cells for example baker's yeast
  • recombinant whole-cell catalysts can correspondingly be used in smaller amounts.
  • a further advantage, in addition to higher reaction rates, is the avoidance of undesirable secondary reactions by further dehydrogenase enzymes contained in wild-type cells.
  • B. coli cells that express an alcohol dehydrogenase and a glucose dehydrogenase for cofactor regeneration have proved to be especially suitable.
  • the object of the present invention was, therefore, to develop a rapid, simple, inexpensive and effective process for the preparation of optically active alcohols from ketones .
  • the object has been achieved according to the invention by a process for the preparation of optically active alcohols by reduction of ketones in the presence of a whole-cell catalyst comprising an alcohol dehydrogenase and also an enzyme capable of cofactor regeneration, characterised in that the conversion of a substrate concentration of at least 500 mM per starting volume of aqueous solvent used is carried out without the addition of an "external" cofactor.
  • a process for the preparation of optically active alcohols by reduction of ketones in the presence of a whole-cell catalyst comprising an alcohol dehydrogenase and also an enzyme capable of cofactor regeneration characterised in that the conversion of a substrate concentration of at least 500 mM per starting volume of aqueous solvent used is carried out without the addition of an "external" cofactor.
  • this is to be understood as meaning that at least 500 mM of the substrate are converted by means of the described process per starting volume of aqueous solvent (including buffer system) used.
  • the process is furthermore particularly suitable for the reduction of ketones using substrate concentrations of >500 mM, preferably >1000 mM and very preferably >1500 mM of ketone.
  • a substrate concentration of at least 500 mM of ketone is actually provided for the conversion.
  • concentrations referred to here relate to concentrations of the substrate (ketone) , based on the starting volume of aqueous solvent, that are actually achieved in the batch, it being immaterial when this starting concentration is achieved in the course of the period of incubation of a whole-cell catalyst that is used.
  • the ketone can be used in these concentrations in the form of a batch directly at the start of a whole-cell batch, or a whole-cell catalyst can first be employed to a particular optical density, before the ketone is added.
  • the ketone can first be used in lower concentrations and added in the course of the incubation period of the cell batch to concentrations as indicated. According to the invention, however, a concentration of substrate (ketone) of at least 500 mM is achieved in the cell batch at least once during the conversion of the substrate to the desired alcohol.
  • the addition of the ketone can be carried out in any desired manner.
  • the total amount of ketone is added at the beginning ("batch” method), or alternatively it is added in metered amounts. It is also possible to employ continuous addition (“continuous feed-in process").
  • optically active alcohols According to the invention, the process described here for the preparation of optically active alcohols is used.
  • the conversion of ketones to optically active alcohols with the aid of alcohol dehydrogenases is known in principle to the person skilled in the art (see the literature references mentioned above) .
  • ketones whose substituents are different from one another In order to obtain optically active alcohols it is particularly preferred to use ketones whose substituents are different from one another.
  • Examples of optically active alcohols which can be prepared from the corresponding ketones are likewise known to the person skilled in the art. They can be subsumed under the following general formula
  • R and R 1 are different from one another and are (C ⁇ -C ⁇ )-al yl, (Ci-C ⁇ ) -alkoxy, HO- (C ⁇ -C 8 ) -alkyl, (C 2 -C 8 )- alkoxyalkyl, (C 6 -C ⁇ 8 ) -aryl, (C7-C19) -aralkyl, (C 3 -C_ .8 )- heteroaryl, (C 4 -C 19 ) -heteroaralkyl, (C ⁇ -C 8 ) -alkyl- (C 6 -C ⁇ 8 )-aryl, (C ⁇ -C 8 ) -alkyl- (C 3 -C ⁇ 8 ) -heteroaryl , (C 3 -C 8 )- cycloalkyl, (C ⁇ -C 8 ) -alkyl- (C 3 -C 8 ) -cycloalkyl, (C 3 -C 8 )
  • the concentration of biocatalyst is not more than 75 g/1, in a preferred embodiment up to 50 g/1, preferably up to 25 g/1 and particularly preferably up to 15 g/1, g being based on g of bio wet mass (BWM) .
  • BWM bio wet mass
  • the biocatalyst is to be understood as being especially a whole-cell catalyst.
  • the conversion of the ketone to the desired optically active alcohol is carried out without the addition of an organic solvent. This is intended to mean that no organic solvent is added to the batch containing the biocatalyst.
  • one of the genes preferably to be selected is a gene for an alcohol dehydrogenase.
  • the person skilled in the art is likewise free to choose the genes that code for such an alcohol dehydrogenase.
  • alcohol dehydrogenases that have proved to be preferable are alcohol dehydrogenases from a Lactobacillus strain, especially from Lactobacillus kefir and Lactobacillus irevis, or alcohol dehydrogenases from a Rhodococcus strain, especially from Rhodococcus erythropolis and Rhodococcus ruber, or alcohol dehydrogenases from an Arthrojacter strain, especially from Arthrobacter paraffineus .
  • a further gene that is particularly preferred for the present invention is a gene that codes for a dehydrogenase.
  • Preferred dehydrogenases for cofactor regeneration have proved to be glucose dehydrogenases, preferably a glucose dehydrogenase from Bacillus, Thermoplasma and Pseudomonas strains, or formate dehydrogenases, preferably a formate dehydrogenase from Candida and Pseudomonas strains, or malate dehydrogenases ("malic enzyme"), preferably a malic enzyme from Sulfolobus, Clostridium, Bacillus and Pseudomonas strains as well as from E. coli , especially E. coli K12.
  • a "whole-cell catalyst” is to be understood as being an intact cell in which at least one gene is expressed that is able to catalyse the conversion according to the invention of a substrate to a product.
  • the intact cell is capable of expressing an alcohol dehydrogenase and a dehydrogenase capable of cofactor regeneration.
  • the whole- cell catalyst is preferably a genetically modified microorganism adapted to the requirements of the desired conversion. Preference is given as particularly suitable whole-cell catalysts to the two whole-cell catalysts described in the experimental part.
  • yeasts such as Hansenula polymorpha , Pichia sp . , Saccharomyces cerevisiae, prokaryotes, such as E. coli , Bacillus subtilis, or eukaryotes, such as mammalian cells, insect cells or plant cells.
  • prokaryotes such as E. coli , Bacillus subtilis, or eukaryotes, such as mammalian cells, insect cells or plant cells.
  • eukaryotes such as mammalian cells, insect cells or plant cells.
  • the cloning methods are well known to the person skilled in the art (Sambrook, J.; Fritsch, E. F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2 nd ed.
  • E. coli strains are preferably to be used for this purpose. Very particular preference is given to: E. coli XLl Blue, NM 522, JM101, JM109, JM105, RRl, DH5 , TOP 10- , HB101, BL21 codon plus, BL21 (DE3) codon plus, BL21, BL21 (DE3), MM294. Plasmids with which the gene construct containing the nucleic acid according to the invention is preferably cloned into the host organism are likewise known to the person skilled in the art (see also PCT/EP03/07148; see below).
  • Suitable plasmids or vectors are in principle any forms available to the person skilled in the art for this purpose.
  • Such plasmids and vectors can be found, for example, in Studier et al . (Studier, W. F.; Rosenberg A. H.; Dunn J. J. ; Dubendroff J. W. ; (1990), Use of the T7 RNA polymerase to direct expression of cloned genes, Methods Enzymol. 185, 61-89) or the brochures of Novagen, Promega, New England Biolabs, Clontech or Gibco BRL. Further preferred plasmids and vectors can be found in: Glover, D. M.
  • Plasmids with which the gene constructs containing the nucleic acid sequences under consideration can very preferably be cloned into the host organism are or are based on: pUC18/19 (Roche Biochemicals) , pKK-177-3H (Roche Bioche icals) , pBTac2 (Roche Biochemicals), pKK223-3 (Amersham Pharmacia Biotech) , pKK-233-3 (Stratagene) or pET (Novagen) .
  • the whole-cell catalyst is preferably pretreated before use in such a manner that the permeability of the cell membrane to the substrates and products is increased compared with the intact system. Particular preference is given to a process in which the whole-cell catalyst is pretreated, for example, by freezing and/or treatment with toluene.
  • the process can be carried out without the addition of an "external" cofactor.
  • Cofactors suitable for the conversion are to be understood as being those to which electrons can be transferred, such as, for example, the NAD(P)+ H + and the FADH 2 system.
  • the process according to the invention can be carried out at any reaction temperatures suitable for the host organism used.
  • a particularly suitable reaction temperature is considered to be a reaction temperature that is from 10 to 90°C, preferably from 15 to 50°C and particularly preferably from 20 to 35°C.
  • the person skilled in the art is also free to choose the pH value of the reaction, it being possible to carry out the reaction both at a fixed pH value and with variation of the pH value within a pH range.
  • the pH value is chosen taking into account in particular the needs of the host organism that is used.
  • the reaction is carried out at a pH value from pH 5 to 9, preferably from pH 6 to 8 and particularly preferably from pH 6.5 to 7.5.
  • the conversion of the substrate used to the desired product is carried out in cell culture using a suitable whole-cell catalyst.
  • a suitable nutrient medium is employed according to the host organism that is used.
  • the media suitable for the host cells are generally known and commercially available. It is additionally possible to add to the cell cultures conventional additives such as, for example, antibiotics, growth-promoting agents such as, for example, serums (foetal calf serum, etc.) and similar known additives .
  • (Ci-C ⁇ ) -Alkyl radicals are to be regarded as being methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl, including all their bond isomers .
  • the radical (C ⁇ -C 8 ) -alkoxy corresponds to the radical (C ⁇ -C 8 ) -alkyl, with the proviso that it is bonded to the molecule via an oxygen atom.
  • (C 2 -C 8 ) -Alkoxyalkyl means radicals in which the alkyl chain is interrupted by at least one oxygen function, wherein two oxygen atoms may not be bonded to one another. The number of carbon atoms indicates the total number of carbon atoms contained in the radical .
  • a (C 3 -C 5 ) -alkylene bridge is a carbon chain having from three to five carbon atoms, the chain being bonded to the molecule under consideration via two different carbon atoms .
  • radicals just described may be mono- or poly- substituted by halogens and/or by radicals containing N, 0, P, S, Si atoms. These are especially alkyl radicals of the above-mentioned type, which contain one or more of these hetero atoms in their chain or which are bonded to the molecule via one of these hetero atoms .
  • (C 3 -C 8 ) -Cycloalkyl is understood as being cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl radicals, etc..
  • These radicals may be substituted by one or more halogens and/or radicals containing N, 0, P, S, Si atoms and/or may contain N, 0, P, S atoms in the ring, such as, for example, 1-, 2-, 3-, 4-piperidyl, 1-, 2-, 3- pyrrolidinyl, 2-, 3-tetrahydrofuryl, 2-, 3-, 4-morpholinyl .
  • a (C 3 -C 8 ) -cycloalkyl- (Ci-C 8 ) -alkyl radical denotes a cycloalkyl radical as described above which is bonded to the molecule via an alkyl radical as indicated above.
  • (C ⁇ -C 8 ) -acyloxy means an alkyl radical as defined above which has not more than 8 carbon atoms and is bonded to the molecule via a COO function.
  • (C ⁇ -C 8 )-acyl means an alkyl radical as defined above which has not more than 8 carbon atoms and is bonded to the molecule via a CO function.
  • a (C ⁇ -Cis) -aryl radical is understood as being an aromatic radical having from 6 to 18 carbon atoms.
  • Such radicals include in particular compounds such as phenyl, naphthyl, anthryl, phenanthryl, biphenyl radicals or systems of the above-described type fused to the molecule in question, such as, for example, indenyl systems, which may optionally be substituted by (C ⁇ -C 8 ) -alkyl, (C ⁇ -C 8 ) -alkoxy, R ⁇ 2 , (Ci-C ⁇ J-acyl, (C ⁇ -C 8 ) -acyloxy.
  • a (C 7 -C ⁇ g) -aralkyl radical is a (Ce-Cis) -aryl radical bonded to the molecule via a (C ⁇ -C 8 ) -alkyl radical.
  • a (C 3 -C ⁇ 8 ) -heteroaryl radical denotes a five-, six- or seven-membered aromatic ring system of from 3 to 18 carbon atoms which contains hetero atoms such as, for example, nitrogen, oxygen or sulfur in the ring.
  • heteroaromatic compounds are regarded as being in particular radicals such as 1-, 2-, 3-furyl, 1-, 2-, 3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl, 3-, 4-, 5-pyrazolyl, 2-, 4-, 5-imidazolyl , acridinyl, quinolinyl, phenanthridinyl , 2-, 4-, 5-, 6-pyrimidinyl .
  • a (C 4 -C 19 ) -heteroaralkyl is understood as being a heteroaromatic system corresponding to the (C 7 -C ⁇ 9 ) -aralkyl radical .
  • Suitable halogens are fluorine, chlorine, bromine and iodine.
  • aqueous solvent is understood as meaning water or a solvent mixture consisting mainly of water with water- soluble organic solvents such as, for example, alcohols, especially methanol or ethanol, or ethers, such as THF or dioxane.
  • Figure 1 shows the plasmid map of plasmid pN05c
  • Figure 2 shows the plasmid map of plasmid pN08c
  • Figure 3 shows the plasmid map of plasmid pN014c
  • E. coli DSM14459 (pN05c,pN08c) was incubated in 2 ml of LB medium with added antibiotic (50 ⁇ g/1 ampicillin and 20 ⁇ g/ml chloramphenicol) for 2 ml of LB medium.
  • antibiotic 50 ⁇ g/1 ampicillin and 20 ⁇ g/ml chloramphenicol
  • Rhodococcus erythropolis (Cloning, sequence analysis and heterologous expression of the gene encoding a (S) -specific alcohol dehydrogenase from Rhodococcus erythropolis DSM 43297. Abokitse, K. ; Hummel, W. Applied Microbiology and Biotechnology 2003, 62 380-386) and a glucose dehydrogenase from Bacillus subtilis (Glucose dehydrogenase from Bacillus subtilis expressed in Escherichia coli. I: Purification, characterization and comparison with glucose dehydrogenase from Bacillus megaterium.
  • E. coli DSM14459 (pN014c) was incubated in 2 ml of LB medium with added antibiotic (50 ⁇ g/1 ampicillin and 20 ⁇ g/ml chloramphenicol) for 18 hours at 37°C, with shaking (250 rpm) .
  • This culture was diluted 1:100 in fresh LB medium with rhamnose (2 g/1) as inducer, added antibiotic (50 ⁇ g/1 ampicillin and 20 ⁇ g/ml chloramphenicol) and 1 mM ZnCl 2 and was incubated for 18 hours at 30°C, with shaking (250 rpm) .
  • the cells were harvested by centrifugation (10,000 g, 10 min., 4°C) , the supernatant was discarded, and the cell pellet was used in biotransformation tests either directly or after storage at -20°C.
  • a Titrino reaction vessel there are added to 50 ml of a phosphate buffer (adjusted to pH 7.0) at room temperature the above-described whole-cell catalyst E. coli DSM14459 (pN05c,pN08c) with an (R) -selective alcohol dehydrogenase (E. coli , (R) -alcohol dehydrogenase from L. kefir, glucose dehydrogenase from T. acidophilum) in a cell concentration of 25 g BWM/1, 1.5 equivalents of glucose (equivalents are based on the amount of p-chloroacetophenone used) and 25 mmol .
  • E. coli DSM14459 pN05c,pN08c
  • an (R) -selective alcohol dehydrogenase E. coli , (R) -alcohol dehydrogenase from L. kefir, glucose dehydrogenase from T. acidophilum
  • acetophenone corresponding to a substrate concentration, based on phosphate buffer used, of 1.5 M
  • the reaction mixture is stirred for 23 hours at room temperature, the pH being kept constant by the addition of sodium hydroxide solution (2M NaOH) .
  • Samples are taken at regular intervals, and the conversion of the acetophenone is determined by means of HPLC. After reaction times of 16.5 and 23 hours, the conversion is 93% and 97%, respectively.
  • the microorganism identified under I. above was accompanied by:
  • This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 20 01 - 0 8 - 22 (Date of the original deposit)'.
  • microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) nnd a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Abstract

The present invention relates to a process for the preparation of optically active alcohols from ketones with the aid of whole-cell catalysts comprising an alcohol dehydrogenase and also an enzyme capable of cofactor regeneration, a substrate concentration of at least 500 mM of ketone being provided for the conversion and the conversion being carried out without the addition of an 'external' cofactor.

Description

PREPARATION OF OPTICALLY ACTIVE ALCOHOLS WITH WHOLE-CELL CATALYSTS
The present invention relates to a process for the preparation of optically active alcohols, starting from ketones, in the presence of a whole-cell catalyst comprising an alcohol dehydrogenase and also an enzyme capable of cofactor regeneration, which process is distinguished in that it is carried out at high substrate concentrations of >500 mM (without the addition of a cofactor) .
The preparation of optically active alcohols is of interest, for example, for the pharmaceuticals industry and the foodstuffs industry. A preferred form of preparation is to obtain the optically active alcohols by reduction of ketones in the presence of alcohol dehydrogenases. This enzymatic reduction of ketones has already been described in detail in the literature. For example, reference may be made here to the overview articles by M.-R. Kula, U. Kragl, Dehydrogenases in the Synthesis of Chiral Compounds in Stereoselective Biocatalysis (ed. : R. N. Patel) , Dekker, 2000, Chapter 28, p. 839-866 and J. D. Stewart, Dehydrogenases and Transaminases in Asymmetric Synthesis in Current Opinion in Chemical Biology 2001, 5, 120-129. Also known in this connection are methods of "regenerating" the cofactor consumed during the reaction. A particularly interesting method of regenerating the cofactors NAD+ or NADP+ consists in using a second dehydrogenase enzyme, in particular a formate dehydrogenase or a glucose dehydrogenase. The use of a whole-cell catalyst for the reduction has proved to be a preferred form of implementation because - in contrast to the use of isolated enzymes in purified form or in the form of their crude extract - there are no additional costs for cell opening and enzyme purification. Likewise preferred is the use of recombinant expression systems, because high rates of expression can be achieved therewith. In comparison with non-recombinant cells, for example baker's yeast, such recombinant whole-cell catalysts can correspondingly be used in smaller amounts. A further advantage, in addition to higher reaction rates, is the avoidance of undesirable secondary reactions by further dehydrogenase enzymes contained in wild-type cells. The advantages of the whole- cell method using microorganisms which have been genetically modified by means of recombinant DNA technology are described in detail, inter alia, in M. Kataoka,
K. Kita, M. ada, Y. Yasohara, J. Hasegawa, S. Shimizu, Appl. Microbiol. Biotechnol . 2003, 62, 437-445. In particular, B. coli cells that express an alcohol dehydrogenase and a glucose dehydrogenase for cofactor regeneration have proved to be especially suitable.
Reductions with high, commercially attractive substrate concentrations have proved to be a particular challenge. Using a whole-cell catalyst in which an ADH and a glucose dehydrogenase were present it has been possible in a two- phase reaction system to produce optically active alcohols even with high substrate concentrations of >500 mM. This has been demonstrated in particular for the preparation of (S) -4-chloro-3-hydroxybutanoic acid ethyl ester. However, it was necessary to add a cofactor, in this case NADP+, for the preparation of these alcohols. As described, for example, in N. Kizaki, Y. Yasohara, J. Hasegawa, M. Wada, M. Kataoka, S. Shimizu, Ap l. Microbiol. Biotechnol. 2001, 55, 590-595, the added amount of NADP+ was in the region of about 0.001 mol . equivalent, based on substrate used. Because of the high price of NADP+, the added cofactor makes a significant contribution to the overall cost of the process even with these relatively small amounts of cofactor. Accordingly, a process that dispenses with the "external addition" of cofactor would be advantageous. Whole-cell transformations (conversion of a substrate by means of whole cells) , based on the activity of an alcohol dehydrogenase and a formate dehydrogenase as cofactor- regenerating enzyme, without the addition of cofactor, have recently been described in A. Matsuyama, H. Yamamoto,
Y. Kobayashi, Organic Process Research & Development 2002, 6, 558-561. However, the substrate concentrations used were below 250 mM (e.g. 196 mM and 217 mM) , and long reaction times of from 17 to 48 hours were required. Corresponding biotransformations with substantially higher substrate concentrations and short reaction times (less than 10 hours) are not known.
The significance of the addition of cofactor for the whole- cell method is also described in N. Itoh, M. Matsuda, M. Mabuchi, T. Dairi, J. Wang, Eur. J. Biochem. 2002, 269, 2394-2402. It was found here that a satisfactory conversion was achieved with the addition of only 0.5 mM, whereas scarcely any product formation took place without the addition of NAD+. In this connection Itoh et al . found that "the endogenous NAD+/NADH in the E. coli cells was insufficient for a smooth reaction" , accompanied by the necessity for the "external" addition of cofactor.
The object of the present invention was, therefore, to develop a rapid, simple, inexpensive and effective process for the preparation of optically active alcohols from ketones .
The object has been achieved according to the invention by a process for the preparation of optically active alcohols by reduction of ketones in the presence of a whole-cell catalyst comprising an alcohol dehydrogenase and also an enzyme capable of cofactor regeneration, characterised in that the conversion of a substrate concentration of at least 500 mM per starting volume of aqueous solvent used is carried out without the addition of an "external" cofactor. According to the invention this is to be understood as meaning that at least 500 mM of the substrate are converted by means of the described process per starting volume of aqueous solvent (including buffer system) used. It can be left open whether the at least 500 mM of substrate are actually achieved as concentration in the reaction mixture, or whether a substrate concentration of at least 500 mM is converted in total, based on the starting volume of aqueous solvent. The process is furthermore particularly suitable for the reduction of ketones using substrate concentrations of >500 mM, preferably >1000 mM and very preferably >1500 mM of ketone.
However, very particular preference is given to the variant in which a substrate concentration of at least 500 mM of ketone is actually provided for the conversion. The concentrations referred to here relate to concentrations of the substrate (ketone) , based on the starting volume of aqueous solvent, that are actually achieved in the batch, it being immaterial when this starting concentration is achieved in the course of the period of incubation of a whole-cell catalyst that is used. The ketone can be used in these concentrations in the form of a batch directly at the start of a whole-cell batch, or a whole-cell catalyst can first be employed to a particular optical density, before the ketone is added. Likewise, the ketone can first be used in lower concentrations and added in the course of the incubation period of the cell batch to concentrations as indicated. According to the invention, however, a concentration of substrate (ketone) of at least 500 mM is achieved in the cell batch at least once during the conversion of the substrate to the desired alcohol.
Using this process, high to very high conversions to the corresponding optically active alcohol of at least 80%, especially >90% and very preferably >95% are surprisingly achieved at high substrate concentrations of at least 500 mM of ketone, especially >750 mM and very preferably >1000 mM even without the addition of an "external" cofactor. This was not to be expected on the basis of the conversions known hitherto and the known problems of the diffusion of the cofactor as a result of the permeabilisation of the cell membrane under the reaction conditions. This is additionally especially surprising because, at the high substrate concentrations of at least 500 mM of hydrophobic ketone component and in view of the low cell concentrations of the biocatalyst of <75 g/1, preferably <50 g/1, permeabilisation of the cell membrane should occur to a particularly great extent, accompanied by a loss of intracellular cofactor by "washing out" of the cofactor into the reaction medium.
The addition of the ketone can be carried out in any desired manner. Preferably, the total amount of ketone is added at the beginning ("batch" method), or alternatively it is added in metered amounts. It is also possible to employ continuous addition ("continuous feed-in process").
According to the invention, the process described here for the preparation of optically active alcohols is used. The conversion of ketones to optically active alcohols with the aid of alcohol dehydrogenases is known in principle to the person skilled in the art (see the literature references mentioned above) . In order to obtain optically active alcohols it is particularly preferred to use ketones whose substituents are different from one another. Examples of optically active alcohols which can be prepared from the corresponding ketones are likewise known to the person skilled in the art. They can be subsumed under the following general formula
Figure imgf000006_0001
in which R and R1 are different from one another and are (Cι-Cβ)-al yl, (Ci-Cβ) -alkoxy, HO- (Cι-C8) -alkyl, (C2-C8)- alkoxyalkyl, (C6-Cι8) -aryl, (C7-C19) -aralkyl, (C3-C_.8)- heteroaryl, (C4-C19) -heteroaralkyl, (Cι-C8) -alkyl- (C6-Cι8)-aryl, (Cι-C8) -alkyl- (C3-Cι8) -heteroaryl , (C3-C8)- cycloalkyl, (Cι-C8) -alkyl- (C3-C8) -cycloalkyl, (C3-C8)- cycloalkyl- (Cι-C8) -alkyl .
The concentration of biocatalyst is not more than 75 g/1, in a preferred embodiment up to 50 g/1, preferably up to 25 g/1 and particularly preferably up to 15 g/1, g being based on g of bio wet mass (BWM) . The biocatalyst is to be understood as being especially a whole-cell catalyst.
In a preferred embodiment, the conversion of the ketone to the desired optically active alcohol is carried out without the addition of an organic solvent. This is intended to mean that no organic solvent is added to the batch containing the biocatalyst.
It is additionally preferred to carry out the conversion in a cell suspension of the suitable whole-cell catalyst, it being possible for the ketone used likewise to be present in the form of a suspension in the cell suspension or in the form of an emulsion or solution in the cell suspension.
For the present invention, one of the genes preferably to be selected is a gene for an alcohol dehydrogenase. The person skilled in the art is likewise free to choose the genes that code for such an alcohol dehydrogenase. Examples of alcohol dehydrogenases that have proved to be preferable are alcohol dehydrogenases from a Lactobacillus strain, especially from Lactobacillus kefir and Lactobacillus irevis, or alcohol dehydrogenases from a Rhodococcus strain, especially from Rhodococcus erythropolis and Rhodococcus ruber, or alcohol dehydrogenases from an Arthrojacter strain, especially from Arthrobacter paraffineus . A further gene that is particularly preferred for the present invention is a gene that codes for a dehydrogenase. Here too, the person skilled in the art is free to choose the genes that code for a dehydrogenase capable of cofactor regeneration. Preferred dehydrogenases for cofactor regeneration have proved to be glucose dehydrogenases, preferably a glucose dehydrogenase from Bacillus, Thermoplasma and Pseudomonas strains, or formate dehydrogenases, preferably a formate dehydrogenase from Candida and Pseudomonas strains, or malate dehydrogenases ("malic enzyme"), preferably a malic enzyme from Sulfolobus, Clostridium, Bacillus and Pseudomonas strains as well as from E. coli , especially E. coli K12.
According to the present invention, a "whole-cell catalyst" is to be understood as being an intact cell in which at least one gene is expressed that is able to catalyse the conversion according to the invention of a substrate to a product. According to the invention, the intact cell is capable of expressing an alcohol dehydrogenase and a dehydrogenase capable of cofactor regeneration. The whole- cell catalyst is preferably a genetically modified microorganism adapted to the requirements of the desired conversion. Preference is given as particularly suitable whole-cell catalysts to the two whole-cell catalysts described in the experimental part.
For the whole-cell catalyst, containing an alcohol dehydrogenase and an enzyme capable of cofactor regeneration, all known cells are suitable. There may be mentioned as microorganisms in this connection organisms such as, for example, yeasts such as Hansenula polymorpha , Pichia sp . , Saccharomyces cerevisiae, prokaryotes, such as E. coli , Bacillus subtilis, or eukaryotes, such as mammalian cells, insect cells or plant cells. The cloning methods are well known to the person skilled in the art (Sambrook, J.; Fritsch, E. F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2nd ed. , Cold Spring Harbor Laboratory Press, New York) . E. coli strains are preferably to be used for this purpose. Very particular preference is given to: E. coli XLl Blue, NM 522, JM101, JM109, JM105, RRl, DH5 , TOP 10- , HB101, BL21 codon plus, BL21 (DE3) codon plus, BL21, BL21 (DE3), MM294. Plasmids with which the gene construct containing the nucleic acid according to the invention is preferably cloned into the host organism are likewise known to the person skilled in the art (see also PCT/EP03/07148; see below).
Suitable plasmids or vectors are in principle any forms available to the person skilled in the art for this purpose. Such plasmids and vectors can be found, for example, in Studier et al . (Studier, W. F.; Rosenberg A. H.; Dunn J. J. ; Dubendroff J. W. ; (1990), Use of the T7 RNA polymerase to direct expression of cloned genes, Methods Enzymol. 185, 61-89) or the brochures of Novagen, Promega, New England Biolabs, Clontech or Gibco BRL. Further preferred plasmids and vectors can be found in: Glover, D. M. (1985) , DNA cloning: a practical approach, Vol. I-III, IRL Press Ltd., Oxford; Rodriguez, R.L. and Denhardt, D. T (eds) (1988), Vectors: a survey of molecular cloning vectors and their uses, 179-204, Butterworth, Stoneham; Goeddel, D. V. (1990) , Systems for heterologous gene expression, Methods Enzymol. 185, 3-7; Sambrook, J. ; Fritsch, E. F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2nd ed. , Cold Spring Harbor Laboratory Press, New York. Plasmids with which the gene constructs containing the nucleic acid sequences under consideration can very preferably be cloned into the host organism are or are based on: pUC18/19 (Roche Biochemicals) , pKK-177-3H (Roche Bioche icals) , pBTac2 (Roche Biochemicals), pKK223-3 (Amersham Pharmacia Biotech) , pKK-233-3 (Stratagene) or pET (Novagen) . In a further embodiment of the process according to the invention, the whole-cell catalyst is preferably pretreated before use in such a manner that the permeability of the cell membrane to the substrates and products is increased compared with the intact system. Particular preference is given to a process in which the whole-cell catalyst is pretreated, for example, by freezing and/or treatment with toluene.
According to the invention, the process can be carried out without the addition of an "external" cofactor. This means that it is not necessary to add additional cofactor to the whole-cell batch, because the cells themselves already contain and are able to use a cofactor suitable for the conversion reaction. Cofactors suitable for the conversion are to be understood as being those to which electrons can be transferred, such as, for example, the NAD(P)+ H+ and the FADH2 system.
The process according to the invention can be carried out at any reaction temperatures suitable for the host organism used. A particularly suitable reaction temperature is considered to be a reaction temperature that is from 10 to 90°C, preferably from 15 to 50°C and particularly preferably from 20 to 35°C.
The person skilled in the art is also free to choose the pH value of the reaction, it being possible to carry out the reaction both at a fixed pH value and with variation of the pH value within a pH range. The pH value is chosen taking into account in particular the needs of the host organism that is used. Preferably, the reaction is carried out at a pH value from pH 5 to 9, preferably from pH 6 to 8 and particularly preferably from pH 6.5 to 7.5.
The conversion of the substrate used to the desired product is carried out in cell culture using a suitable whole-cell catalyst. A suitable nutrient medium is employed according to the host organism that is used. The media suitable for the host cells are generally known and commercially available. It is additionally possible to add to the cell cultures conventional additives such as, for example, antibiotics, growth-promoting agents such as, for example, serums (foetal calf serum, etc.) and similar known additives .
(Ci-Cβ) -Alkyl radicals are to be regarded as being methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl, including all their bond isomers .
The radical (Cι-C8) -alkoxy corresponds to the radical (Cι-C8) -alkyl, with the proviso that it is bonded to the molecule via an oxygen atom. (C2-C8) -Alkoxyalkyl means radicals in which the alkyl chain is interrupted by at least one oxygen function, wherein two oxygen atoms may not be bonded to one another. The number of carbon atoms indicates the total number of carbon atoms contained in the radical . A (C3-C5) -alkylene bridge is a carbon chain having from three to five carbon atoms, the chain being bonded to the molecule under consideration via two different carbon atoms . The radicals just described may be mono- or poly- substituted by halogens and/or by radicals containing N, 0, P, S, Si atoms. These are especially alkyl radicals of the above-mentioned type, which contain one or more of these hetero atoms in their chain or which are bonded to the molecule via one of these hetero atoms .
(C3-C8) -Cycloalkyl is understood as being cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl radicals, etc.. These radicals may be substituted by one or more halogens and/or radicals containing N, 0, P, S, Si atoms and/or may contain N, 0, P, S atoms in the ring, such as, for example, 1-, 2-, 3-, 4-piperidyl, 1-, 2-, 3- pyrrolidinyl, 2-, 3-tetrahydrofuryl, 2-, 3-, 4-morpholinyl .
A (C3-C8) -cycloalkyl- (Ci-C8) -alkyl radical denotes a cycloalkyl radical as described above which is bonded to the molecule via an alkyl radical as indicated above.
Within the scope of the invention, (Cι-C8) -acyloxy means an alkyl radical as defined above which has not more than 8 carbon atoms and is bonded to the molecule via a COO function.
Within the scope of the invention, (Cχ-C8)-acyl means an alkyl radical as defined above which has not more than 8 carbon atoms and is bonded to the molecule via a CO function.
A (Cδ-Cis) -aryl radical is understood as being an aromatic radical having from 6 to 18 carbon atoms. Such radicals include in particular compounds such as phenyl, naphthyl, anthryl, phenanthryl, biphenyl radicals or systems of the above-described type fused to the molecule in question, such as, for example, indenyl systems, which may optionally be substituted by (Cι-C8) -alkyl, (Cι-C8) -alkoxy, R^2, (Ci-CβJ-acyl, (Cι-C8) -acyloxy.
A (C7-Cιg) -aralkyl radical is a (Ce-Cis) -aryl radical bonded to the molecule via a (Cι-C8) -alkyl radical.
Within the scope of the invention, a (C3-Cι8) -heteroaryl radical denotes a five-, six- or seven-membered aromatic ring system of from 3 to 18 carbon atoms which contains hetero atoms such as, for example, nitrogen, oxygen or sulfur in the ring. Such heteroaromatic compounds are regarded as being in particular radicals such as 1-, 2-, 3-furyl, 1-, 2-, 3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl, 3-, 4-, 5-pyrazolyl, 2-, 4-, 5-imidazolyl , acridinyl, quinolinyl, phenanthridinyl , 2-, 4-, 5-, 6-pyrimidinyl . A (C4-C19) -heteroaralkyl is understood as being a heteroaromatic system corresponding to the (C7-Cι9) -aralkyl radical .
Suitable halogens (Hal) are fluorine, chlorine, bromine and iodine.
The term aqueous solvent is understood as meaning water or a solvent mixture consisting mainly of water with water- soluble organic solvents such as, for example, alcohols, especially methanol or ethanol, or ethers, such as THF or dioxane.
Figures :
Figure 1 shows the plasmid map of plasmid pN05c
Figure 2 shows the plasmid map of plasmid pN08c
Figure 3 shows the plasmid map of plasmid pN014c
Examples :
Preparation of a whole-cell catalyst comprising an (R)- alcohol dehydrogenase from Lactobacillus kefir and a glucose dehydrogenase from Thermoplasma acidophilum
Preparation of the strain
Chemically competent cells of E. coli DSM14459 (described in WO03/042412) were transformed with the plasmid pN05c (Sambrook et al . 1989, Molecular cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press) . This plasmid codes for the alcohol dehydrogenase from Lactobacill us kefir (Lactobacillus kefir alcohol dehydrogenase: a useful catalyst for synthesis. Bradshaw et al . JOC 1992, 57 1532-6, Reduction of acetophenone to R(+)- phenylethanol by a new alcohol dehydrogenase from Lactobacillus kefir. Hummel W. Ap Microbiol Biotech 1990, 34, 15-19) . The recombinant strain E. coli DSM14459 (pN05c) so prepared was made chemically competent and transformed with the plasmid pN08c, which codes for the gene of a codon-optimised glucose dehydrogenase from Thermoplasma acidophilum (Bright, J.R. et al . , 1993 Eur. J. Biochem. 211:549-554). Both genes are under the control of a rhamnose promoter (Stumpp, Tina; Wilms, Burkhard; Altenbuchner, Josef. A new, L-rhamnose-inducible expression system for Escherichia coli. BlOspektrum (2000), 6(1), 33-36). The sequences and plasmid maps of pN05c and pN08c are shown hereinbelow.
Preparation of active cells
An individual colony of E. coli DSM14459 (pN05c,pN08c) was incubated in 2 ml of LB medium with added antibiotic (50 μg/1 ampicillin and 20 μg/ml chloramphenicol) for
18 hours at 37°C, with shaking (250 rpm) . This culture was diluted 1:100 in fresh LB medium with rhamnose (2 g/1) as inducer, added antibiotic (50 μg/1 ampicillin and 20 μg/ml chloramphenicol) and 1 mM ZnCl2 and was incubated for 18 hours at 30°C, with shaking (250 rpm) . The cells were then harvested by centrifugation (10,000 g, 10 min. , 4°C) , the supernatant was discarded, and the cell pellet was used in biotransformation tests either directly or after storage at -20°C.
Preparation of a whole-cell catalyst comprising an (S)- alcohol dehydrogenase from Rhodococcus erythropolis and a glucose dehydrogenase from Bacillus subtilis
Preparation of the strain
Chemically competent cells of E. coli DSM14459 (described in WO03/042412) were transformed with the plasmid pN014c (Sambrook et al . 1989, Molecular cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press) . This plasmid codes for an alcohol dehydrogenase from
Rhodococcus erythropolis (Cloning, sequence analysis and heterologous expression of the gene encoding a (S) -specific alcohol dehydrogenase from Rhodococcus erythropolis DSM 43297. Abokitse, K. ; Hummel, W. Applied Microbiology and Biotechnology 2003, 62 380-386) and a glucose dehydrogenase from Bacillus subtilis (Glucose dehydrogenase from Bacillus subtilis expressed in Escherichia coli. I: Purification, characterization and comparison with glucose dehydrogenase from Bacillus megaterium. Hilt W; Pfleiderer G; Fortnagel P Biochimica et biophysica acta (1991 Jan 29), 1076(2), 298-304) . The alcohol dehydrogenase is under the control of a rhamnose promoter (Stumpp, Tina; Wilms, Burkhard; Altenbuchner, Josef. A new, L-rhamnose-indueible expression system for Escherichia coli. BlOspektrum (2000), 6(1), 33-36). The sequence and plasmid map of pN014c is shown hereinbelow. Preparation of active cells
An individual colony of E. coli DSM14459 (pN014c) was incubated in 2 ml of LB medium with added antibiotic (50 μg/1 ampicillin and 20 μg/ml chloramphenicol) for 18 hours at 37°C, with shaking (250 rpm) . This culture was diluted 1:100 in fresh LB medium with rhamnose (2 g/1) as inducer, added antibiotic (50 μg/1 ampicillin and 20 μg/ml chloramphenicol) and 1 mM ZnCl2 and was incubated for 18 hours at 30°C, with shaking (250 rpm) . The cells were harvested by centrifugation (10,000 g, 10 min., 4°C) , the supernatant was discarded, and the cell pellet was used in biotransformation tests either directly or after storage at -20°C.
Synthesis Example 1: Reduction of p-chloroacetophenone in a 0.5 M solution using a whole-cell catalyst comprising an (R) -selective alcohol dehydrogenase
In a Titrino reaction vessel there are added to 50 ml of a phosphate buffer (adjusted to pH 7.0) at room temperature the above-described whole-cell catalyst E. coli DSM14459 (pN05c,pN08c) with an (R) -selective alcohol dehydrogenase (E. coli , (R) -alcohol dehydrogenase from L. kefir, glucose dehydrogenase from T. acidophilum) in a cell concentration of 25 g BWM/1, 1.5 equivalents of glucose (equivalents are based on the amount of p-chloroacetophenone used) and 25 mmol . of p-chloroacetophenone (corresponding to a substrate concentration, based on phosphate buffer used, of 0.5 M) . The reaction mixture is stirred for 7 hours at room temperature, the pH being kept constant by the addition of sodium hydroxide solution (1M NaOH) . Samples are taken at regular intervals, and the conversion of the p-chloroacetophenone is determined by means of HPLC. After a reaction time of 7 hours, the conversion is >99%. Synthesis Example 2: Reduction of p-chloroacetophenone in a 0.5 M solution using a whole-cell catalyst comprising an (S) -selective alcohol dehydrogenase
In a Titrino reaction vessel there are added to 50 ml of a phosphate buffer (adjusted to pH 7.0) at room temperature the above-described whole-cell catalyst E. coli DSM14459 (pN014c) with an ( S) -selective alcohol dehydrogenase (E. coli , (S) -alcohol dehydrogenase from R . erythropolis, glucose dehydrogenase from B . subtilis) in a cell concentration of 50 g BWM/1, 6 equivalents of glucose (equivalents are based on the amount of p-chloroacetophenone used) and 25 mmol. of p-chloroacetophenone (corresponding to a substrate concentration, based on phosphate buffer used, of 0.5 M) . The reaction mixture is stirred for 7.5 hours at room temperature, the pH being kept constant by the addition of sodium hydroxide solution (1M NaOH) . Samples are taken at regular intervals, and the conversion of the p-chloroacetophenone is determined by means of HPLC. After a reaction time of 7.5 hours, the conversion is 92%.
Synthesis Example 3 : Reduction of acetophenone in a 1.5 M solution using a whole-cell catalyst comprising an (R)- selective alcohol dehydrogenase
In a Titrino reaction vessel there are added to 40 ml of a phosphate buffer (adjusted to pH 7.0) at room temperature the above-described whole-cell catalyst E. coli DSM14459 (pN05c,pN08c) with an (R) -selective alcohol dehydrogenase (E. coli , (R) -alcohol dehydrogenase from L. kefir, glucose dehydrogenase from T. acidophilum) in a cell concentration giving an optical density of OD = 21.15, 1.05 equivalents of glucose (equivalents are based on the amount of acetophenone used) and 60 mmol. of acetophenone (corresponding to a substrate concentration, based on phosphate buffer used, of 1.5 M) . The reaction mixture is stirred for 23 hours at room temperature, the pH being kept constant by the addition of sodium hydroxide solution (2M NaOH) . Samples are taken at regular intervals, and the conversion of the acetophenone is determined by means of HPLC. After reaction times of 16.5 and 23 hours, the conversion is 93% and 97%, respectively.
BUDAPEST TREATY ON THE INTERNATIONAL ECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
Degussa AG Projekthaus Biotechnologie Rodenbacher Chaussee 63457 Hanau VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page
Figure imgf000019_0001
' Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer). 2 In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test. 1 Mark with a cross the applicable box. * Fill in if the information has been requested and if the results of the test were negative Form DSMZ-BP/9 (sole page) 0196 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM
Degussa AG Projekthaus Biotechnologie Rodenbacher Chaussee 63457 Hanau RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page
I. IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the DEPOSITOR: Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:
JM109 (deltarhaB) DSM 14459
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONO IC DESIGNATION
The microorganism identified under I. above was accompanied by:
( ) a scientific description (X ) a proposed taxoπomic designation
(Mark with a cross where applicable).
Ill RECEIPT AND ACCEPTANCE
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 20 01 - 0 8 - 22 (Date of the original deposit)'.
IV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) nnd a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).
V INTERNATIONAL DEPOSITARY AUTHORITY
Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of person(s) having the power to represent the MIK.ROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized offιcial(s):
Address. Mascheroder Weg lb D-38I24 Braunschweig c . OC/Λ £ Date 2 0 01 - 0 8 - 24
' Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired Form DSMZ-BP/4 (sole page) 0196

Claims

21Claims :
1. Process for the preparation of optically active alcohols by reduction of ketones in the presence of a whole-cell catalyst comprising an alcohol dehydrogenase and also an enzyme capable of cofactor regeneration, characterised in that the conversion of a substrate concentration of at least 500 mM per starting volume of aqueous solvent used is carried out without the addition of an "external" cofactor.
2. Process according to claim 1, characterised in that a substrate concentration of at least 500 mM of ketone is provided for the conversion.
3. Process according to claim 1 and/or 2, characterised in that the concentration of biocatalyst used does not exceed 75 g/1.
4. Process according to claim 1 to 3, characterised in that the process is carried out in the absence of an organic solvent.
5. Process according to any one of claims 1 to 4, characterised in that there is used a whole-cell catalyst comprising at least one alcohol dehydrogenase selected from the group consisting of an alcohol dehydrogenase from a Lactobacillus strain, especially from Lactobacillus kefir and Lactobacillus brevis, and/or an alcohol dehydrogenase from a Rhodococcus strain, especially from Rhodococcus erythropolis and Rhodococcus ruber, and/or an alcohol dehydrogenase from an Arthrobacter strain, especially from Arthroiacter paraffineus .
6. Process according to any one of claims 1 to 5, characterised in that the whole-cell catalyst comprises as an enzyme capable of cofactor 22
regeneration a glucose dehydrogenase, preferably from Bacillus , Thermoplasma and Pseudomonas strains.
7. Process according to any one of claims 1 to 6, characterised in that the whole-cell catalyst comprises as an enzyme capable of cofactor regeneration a formate dehydrogenase, preferably from Candida and Pseudomonas strains.
8. Process according to any one of claims 1 to 7, characterised in that the whole-cell catalyst comprises as an enzyme capable of cofactor regeneration a malate dehydrogenase.
9. Process according to any one of claims 1 to 8, characterised in that the reaction temperature is from 10 to 90°C, preferably from 15 to 50°C and very preferably from 20 to 35°C.
10. Process according to any one of claims 1 to 9 , characterised in that the pH value is from pH 5 to 9, preferably from pH 6 to 8 and particularly preferably from 6.5 to 7.5.
11. Process according to any one of claims 1 to 10, characterised in that the total amount of substrate is added at the beginning.
12. Process according to any one of claims 1 to 11, characterised in that the substrate is metered in during the reaction.
PCT/EP2005/006215 2004-06-14 2005-06-09 Preparation of optically active alcohols with whole-cell catalysts Ceased WO2005121350A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT05757030T ATE491036T1 (en) 2004-06-14 2005-06-09 PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS USING WHOLE CELL CATALYSTS
CN200580019379XA CN101098967B (en) 2004-06-14 2005-06-09 Preparation of optically active alcohols with whole-cell catalysts
DE602005025225T DE602005025225D1 (en) 2004-06-14 2005-06-09 PREPARATION OF OPTICALLY ACTIVE ALCOHOLS WITH ALL-CELL CATALYSTS
JP2007515834A JP2008502334A (en) 2004-06-14 2005-06-09 Production method of optically active alcohol using whole cell catalyst
US11/629,407 US20090258405A1 (en) 2004-06-14 2005-06-09 Preparation of optically active alcohols with whole-cell catalysts
EP05757030A EP1774009B1 (en) 2004-06-14 2005-06-09 Preparation of optically active alcohols with whole-cell catalysts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004028407.5 2004-06-14
DE102004028407A DE102004028407A1 (en) 2004-06-14 2004-06-14 Preparation of optically active alcohols with the aid of whole-cell catalysts

Publications (1)

Publication Number Publication Date
WO2005121350A1 true WO2005121350A1 (en) 2005-12-22

Family

ID=34971682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006215 Ceased WO2005121350A1 (en) 2004-06-14 2005-06-09 Preparation of optically active alcohols with whole-cell catalysts

Country Status (7)

Country Link
US (1) US20090258405A1 (en)
EP (1) EP1774009B1 (en)
JP (1) JP2008502334A (en)
CN (1) CN101098967B (en)
AT (1) ATE491036T1 (en)
DE (2) DE102004028407A1 (en)
WO (1) WO2005121350A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008000136A (en) * 2006-06-21 2008-01-10 Degussa Gmbh Post-treatment of reaction solution from whole cell-in vivo conversion

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007060705A1 (en) * 2007-12-17 2009-06-18 Evonik Degussa Gmbh ω-aminocarboxylic acids or their lactams, producing, recombinant cells
CN112941115B (en) * 2021-03-30 2024-08-16 江苏阿尔法集团盛基药业(宿迁)有限公司 Ticagrelor chiral preparation method of intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022764A2 (en) * 2002-09-03 2004-03-18 Degussa Ag Use of malate dehydrogenase for nadh regeneration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0875562A4 (en) * 1996-10-22 2004-11-17 Daicel Chem NOVEL SECONDARY ALCOHOL DEHYDROGENASE, PROCESS FOR PREPARING THIS ENZYME AND PROCESS FOR PREPARING ALCOHOLS AND KETONS USING THIS ENZYME
US6713288B1 (en) * 1999-09-28 2004-03-30 University Of Stuttgart Whole cell catalysts
CN1127566C (en) * 1999-12-24 2003-11-12 中国科学院上海有机化学研究所 Geotrichosis candium strain and its culture process and application
US20060172366A1 (en) * 2002-07-20 2006-08-03 Degussa Ag Two-phase alocohol dehydrogenase-based coupled enzymatic reaction system
JP2005533496A (en) * 2002-07-20 2005-11-10 デグサ アクチエンゲゼルシャフト Conjugated enzyme reaction system using formate dehydrogenase derived from Candida voyinii

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022764A2 (en) * 2002-09-03 2004-03-18 Degussa Ag Use of malate dehydrogenase for nadh regeneration

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMIDJOJO, M.H.: "Reaktionstechnische Untersuchungen zur asymmetrischen Synthese von chiralen Alkoholen mit Lactobacillus kefir", December 2004 (2004-12-01), pages 1 - 2, XP002344757, Retrieved from the Internet <URL:http://tumb1.biblio.tu-muenchen.de/publ/diss/mw/2004/amidjojo.html> [retrieved on 20050913] *
ERNST ET AL: "Enantioselective reduction of carbonyl compounds by whole-cell biotransformation, combining a formate dehydrogenase and a (R)-specific alcohol dehydrogenase", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 66, November 2004 (2004-11-01), pages 629 - 634, XP002344978 *
GRÖGER ET AL: "Practical asymmetric enzymatic reduction through diuscovery of a dehydrogenase-compatible biphasic reaction media", ORGANIC LETTERS, vol. 5, 2003, pages 173 - 176, XP001154877 *
GRÖGER ET AL: "Preparative asymmetric reduction of ketones in a biphasic medium with an (S)-alcohol dehydrogenase under in situ-cofactor-recycling with a formate dehydrogenase", TETRAHEDRON, vol. 60, January 2004 (2004-01-01), pages 633 - 640, XP004482876 *
MATSUYAMA ET AL: "Practical application of recombinant whole-cell biocatalysts for the manufacturing of pharmaceutical intermediates such as chiral alcohols", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 6, 2002, pages 558 - 561, XP002344756 *
WECKBECKER ET AL: "Improved synthesis of chiral alcohols with Escherichia coli cells co-expressing pyridine nucleotide transhydrogenase, NADP(+)-dependent alcohol dehydrogenase and NAD(+)-dependent formate dehydrogenase", BIOTECHNOLOGY LETTERS, vol. 26, November 2004 (2004-11-01), pages 1739 - 1744, XP002344979 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008000136A (en) * 2006-06-21 2008-01-10 Degussa Gmbh Post-treatment of reaction solution from whole cell-in vivo conversion
US8613857B2 (en) * 2006-06-21 2013-12-24 Evonik Degussa Gmbh Processing of reaction solutions from whole-cell biotransformations

Also Published As

Publication number Publication date
ATE491036T1 (en) 2010-12-15
DE102004028407A1 (en) 2005-12-29
CN101098967B (en) 2012-01-04
JP2008502334A (en) 2008-01-31
US20090258405A1 (en) 2009-10-15
DE602005025225D1 (en) 2011-01-20
CN101098967A (en) 2008-01-02
EP1774009B1 (en) 2010-12-08
EP1774009A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
CA2653028C (en) Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids
US20140065697A1 (en) Cells and methods for producing isobutyric acid
US7435574B2 (en) NADH oxidase from Lactobacillus
CN105358687B (en) Designer cells and their applications for the enantioselective reduction of ketones in the efficient production of enantiomerically enriched alcohols
EP1499716B1 (en) Adh from rhodococcus erythropolis
EP1774009B1 (en) Preparation of optically active alcohols with whole-cell catalysts
US20080145904A1 (en) Method For Producing Primary Alcohols
WO2008035187A2 (en) Alcohol dehydrogenase from agromyces sp. and a method of producing a chiral secondary alcohol using same
CN116064441B (en) L-pantolactone dehydrogenase mutant and its encoding gene and application
Martínez‐Martínez et al. High‐level production of Bacillus subtilis glycine oxidase by fed‐batch cultivation of recombinant Escherichia coli Rosetta (DE3)
US7247465B2 (en) Screening process for hydantoin racemases
CA2497499A1 (en) Use of malate dehydrogenase for nadh regeneration
CA2442561C (en) Method for the oxidation of aromatic compounds
WO2006027081A1 (en) Biocatalyst for hydrolyzing cyanide
KR102890220B1 (en) Chemoenzymatic method for co-production of disulfides and sulfoxides or sulfones
EP1945785A1 (en) Process for preparing 1,1,1-trifluoroisopropanol predominantly comprising one enantiomer
WO2007028729A1 (en) Nocardia globerula alcohol dehydrogenase and use thereof
JP2015515866A (en) Biosynthetic pathways, recombinant cells and methods
CA2559361C (en) Expression of nitrile hydratases in a two-vector expression system
KR20240158396A (en) Method for producing xylitol from xylose by using yahk
WO2004005517A2 (en) L-amidase from rhizobium huautlense
KR20180082079A (en) Process for preparing 2,3-butanediol using transformant
WO2005044973A2 (en) NOVEL ACETOACETYL-CoA REDUCTASE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL
WO2004048561A1 (en) Enzymatic reaction system comprising a pqq-dependent alcohol dehydrogenase and a quinoid redox cofactor compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005757030

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3515/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580019379.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007515834

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2005757030

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11629407

Country of ref document: US